The month ahead: April’s upcoming events
April will see the first big scientific meeting of the year, and could herald important data from Immutep and GSK.
April will see the first big scientific meeting of the year, and could herald important data from Immutep and GSK.
A roundup of the first quarter's key oncology drug approvals and rejections.
Checkmate-9DW scores a topline win on overall survival, when failure seemed more likely.
The micro cap promises data this year, but its peer Kineta winds down a VISTA trial.